
mRNAã¯ã¯ãã³ãå®å šæ§ãæ€èšŒããªããŸãŸéçºã©ãã·ã¥ïŒ
ãªãŒã¹ãã©ãªã¢ã§ã¯ãå®¶çåãã®mRNAã¯ã¯ãã³ã®éçºãæ¥ãããã§é²ããããŠããŸããmRNAã¯ã¯ãã³ãæ¥çš®ããçŸãçã«ãå¯åå¿ã¯ãªãã®ã§ãããããä»åŸããªãŒãžãŒããŒããªã©ã®å®å
šæ§ã¯ã©ããã£ãŠç¢ºèªãããã®ã§ãããããæ¥æ¬ã§ã¯ãåå°ã«mRNAã¯ã¯ãã³ã®çç£å·¥å ŽãäœãããŠããŸããã€ã³ãã«ãšã³ã¶ã®mRNAã¯ã¯ãã³ãéçºãããŠãããå®å
šæ§ãæ€èšŒãããªããŸãŸãmRNAã¯ã¯ãã³ã®çç£æºåãå éããŠããŸãã
ãªãŒã¹ãã©ãªã¢ã§ã®ã¯ã¯ãã³éçº
ãã¥ãŒãµãŠã¹ãŠã§ãŒã«ãºå·æ¿åºã¯ãå®¶çåãã®mRNAã¯ã¯ãã³ãéçºããããã«ã2022幎9æã«ã¢ã¡ãªã«ã®ãã€ãªãã¯ãããžãŒäŒæ¥ ãTiba Biotechã ãšææºããŸããïŒäžèšãªãªãŒã¹åç §ïŒã
ã€ã³ããã·ã¢ã§çã«ã©ã³ããŒã¹ãã³ç (Lumpy Skin DiseaseïŒLSD) ãšå£è¹ç« (Foot and Mouth DiseaseïŒFMD) ãçºçããããšããæå€§ã®æžå¿µãšãªã£ãŠããããã§ãããªãŒã¹ãã©ãªã¢ã§ã¯ãŸã çºçããŠããŸããããä»åŸçºçããå Žåãè«å€§ãªçµæžæå€±ãäžããããšã瀺åãããŠãããããã¯ã¯ãã³éçºã«çæãããšã®ããšã
以äžããªãŒã¹ãã©ãªã¢ã®äž»èŠæ¿å ãThe Nationalsãã®ãã¥ãŒã¹ãµã€ãããåŒçšã§ããThe NationalsïŒãªãŒã¹ãã©ãªã¢åœæ°å ïŒã¯ã蟲æ°ãå°æ¹åšäœè ã®å©çãå®ãããšãç®çã« 1914幎ã«å°æ¹å ãšããŠã¹ã¿ãŒãããå ãšã®ããšã§ãã
23 Feb, 2023
The NSW Nationals in government have taken another step forward in the mission to develop world first mRNA vaccines against exotic livestock diseases, with sheep being given a trial mRNA vaccine for Border Disease at the Elizabeth Macarthur Agricultural Institute this week.
2023幎2æã®èšäºã«ãããŒããŒç ïŒBorder DiseaseïŒã®çŸã«ã詊éšçã«mRNAã¯ã¯ãã³ãæ¥çš®ãããšããããã¥ãŒãµãŠã¹ãŠã§ãŒã«ãºå·å¯éŠçžå Œå°æ¹å€§è£ã®ããŒã«ã»ãã¥ãŒã«æ°ã¯ãã2023幎8æã®å®çšåã«åããŠãçŽ æŽããã鲿©ã§ããããšèªã£ãŠããŸããã€ãŸããçç£éšéããä¿è·ãããããã«é²ããŠãããšèšã£ãŠããã®ã§ãã
ããã©ãããã¥ãŒãµãŠã¹ãŠã§ãŒã«ãºå·æ¿åºããTiba Biotechã ãšææºããã®ã¯ã2022幎9æã§ããçŽ1幎ã§å®çšåãç®æããšããã®ã¯ãå®¶çã®å®å šæ§ã ãã§ãªãããããé£ã¹ã人ã®å®å šæ§ãªã©ã®ç¢ºèªãããã«ã¯æéãçããããšæããŸãããããªã«æ¥ãã§éçºãé²ããããšããæ¬åœã«ãä¿è·ãããããšã«ãªãã®ã§ããããã
ãããã®ãŸãŸå®çšåãããã°ãæ¥æ¬ã«ããã®æµãã¯æ¥ãã§ãããããããªã£ããšããé ªèŸ²å®¶ãçç£å®¶ã®æ¹ãã¡ã¯ã©ã®ãããªå€æãããã®ã§ããããã
çµæžçãªæå€±ãé¿ãããã®ã¯åœç¶ã§ããããã©ããå®¶çã®å®å šæ§ãçç£ããããã®ãé£ã¹ãã飲ãã ããããããžã®å®å šæ§ã«äžå®ãããäžã§ãmRNAã¯ã¯ãã³ã䜿ãããšãäœãæå³ããã®ããæ éã«èããªããã°ãªããªããšæããŸããmRNAã¯ã¯ãã³ã䜿ãåã«ãæ¿åºã¯å šé 矜殺åŠåãèŠçŽããªã©ã蟲家ãå®ãããã«ã§ããããšãããã®ã§ã¯ãªãã§ããããã
å°å ¥ãããŠããŸã£ãããæ¶è²»è ã«é£ã¹ç©ãéžã¶æš©å©ãæ®ãããã®ãããããŸãããã§ããããæ¶è²»è ãäžç·ã«èããªããã°ãªããªããšæããŸãã
æ¥æ¬ã§ã¯å·¥å Žãç¶ã èªç
åœå ã§ã¯ãmRNAã¯ã¯ãã³ã®çç£å·¥å Žããç¶ã èªçããŠããŸãã
äžèšã¯ãçŠå³¶çåçžéЬã®å·¥å Žã
ãã¯ã¯ãã³å·¥å Žãå°é®ç¥ãåçžéЬã®å·¥æ¥å£å°ãïœïŒ²ïŒ®ïŒ¡å»è¬å補é
2022幎03æ13æ¥ 06æ45åãçŠå³¶æ°åæ°è
åçžéЬåžåçºåºã®äžå€ªç°å·¥æ¥å£å°ã«é²åºããå»è¬ååèšè£œé ã¢ã«ã«ãªã¹ïŒåèçïŒã®éºäŒç©è³ªã¡ãã»ã³ãžã£ãŒïŒ²ïŒ®ïŒ¡ïŒïœïŒ²ïŒ®ïŒ¡ïŒã«ç¹åããå»è¬åã»ã¯ã¯ãã³è£œé å·¥å Žã®å°é®ç¥ã¯ïŒïŒæ¥ãçŸå°ã§è¡ããããïœïŒ²ïŒ®ïŒ¡ã¯ç±³ãã¡ã€ã¶ãŒè£œãªã©æ°åã³ãããŠã€ã«ã¹ã®ã¯ã¯ãã³ã§æ³šç®ãããå 端æè¡ã§ã補é å·¥å Žã®å»ºèšã¯åœå åãæ°åã³ããã®ã¯ã¯ãã³è£œé ãèšç»ããŠããã
å®å šæ§ã®æ€èšŒãããã«ãã³ããã¯ã¯ãã³ã®æ¥çš®ã¯ãã£ãšç¶ããšããããšã®ããã§ãã
ããã«ãææ²»ã°ã«ãŒãã®è£œè¬äŒç€ŸãMeiji Seika ãã¡ã«ããããã¢ã¡ãªã«ã®äŒæ¥ãéçºããæ°åã³ãããŠã€ã«ã¹ã®æ¬¡äžä»£ã¡ãã»ã³ãžã£ãŒRNAã¯ã¯ãã³ãARCT-154ããåœå ã§è£œé 販売ã§ããããæ¿èªç³è«ãããš4æ28æ¥ã«çºè¡šããŸããããã®ã¯ã¯ãã³ã®è£œé ã¯æ ªåŒäŒç€Ÿ ARCALIS ïŒã¢ã«ã«ãªã¹ïŒãšé£æºããå瀟ã建èšäžã®è£œé æœèš(çŠå³¶çåçžéЬåž)ã§åè¬ãã補å€ãŸã§äžè²«ããŠè£œé ã§ããäœå¶ã®æ§ç¯ãé²ããŠãããšã®ããšã
ãæäººã«ãããååå ç«ïŒ2 åæ¥çš®ïŒã«ãã COVID-19 ã®äºé²ããé©å¿çãšããŠç³è«ãããšãããŸãããèšåºè©Šéšã¯äœäººãããè¡ã£ãã®ã§ãããããååæ¥çš®ãããŠããªã人ã¯ãä»åŸãæ¥çš®ããã€ããã¯ãªã人ãã»ãšãã©ã ãšæãã®ã§ãèšåºè©Šéšã«åå ããäººãæ¢ãã®ã¯é£ãããšæããŸãã
第äžäžå ±ã¯ãåŒççã®å·¥å Žãå¢åŒ·ã
ã³ããã¯ã¯ãã³çç£ãžå·¥å Žå¢åŒ·ã第äžäžå ±ã幎éïŒïŒïŒïŒäžåå
2023.2.6ãé岡æ°è
ã第äžäžå ±ããéçºäžã®æ°åã³ãããŠã€ã«ã¹ã¯ã¯ãã³ã補é ããåŒççã®åäŒç€Ÿå·¥å Žãå¢åŒ·ããïŒïŒïŒïŒå¹ŽåºŠãŸã§ã«å¹ŽéïŒåäžååãçç£ã§ããäœå¶ãæŽåããããšãïŒæ¥ãåãã£ããä»å¹ŽïŒæã«åçåŽåçãžè£œé è²©å£²ã®æ¿èªç³è«ãè¡ãã幎å ã®å®çšåãç®æããŠããã
第äžäžå ±ã¯ãåœå ã®è£œè¬äŒç€Ÿã§åããŠãmRNAã³ããã¯ã¯ãã³ã®æ¿èªç³è«ããããš1æ13æ¥ã«çºè¡šããŸããïŒäžèšåç §ïŒã
ã¿ã«ã©ãã€ãªã¯ãæ»è³çã®æ¬ç€Ÿæ·å°å ã«å·¥å Žãæ°èšã
ã¯ã¯ãã³çç£ãïŒïŒå¹ŽåºŠïŒåã«ãã¿ã«ã©ãã€ãªãå·¥å Žãæ°èš
2022.12.5ãé岡æ°è
ãã¿ã«ã©ãã€ãªã¯ïŒæ¥ãæ°åã³ãããŠã€ã«ã¹ãªã©ã«å¯Ÿå¿ããã¯ã¯ãã³ã®åèšè£œé ã®èœåã匷åãããšæããã«ãããæ»è³çèæŽ¥åžã®æ¬ç€Ÿæ·å°å ã«å·¥å Žãæ°èšããæ°åã³ããã¯ã¯ãã³æç®ã§çŸåšã®å¹ŽéçŽïŒïŒïŒïŒäžååã®çç£èœåããïŒïŒïŒïŒå¹ŽåºŠã«ãçŽïŒåã®çŽïŒåäžååã«å¢åŒ·ããã
ãæ°åã³ããã«éããã¡ãã»ã³ãžã£ãŒïŒ²ïŒ®ïŒ¡ïŒïœïŒ²ïŒ®ïŒ¡ïŒã䜿ã£ãã¯ã¯ãã³ã®è£œé ãå¯èœã§ãæ°ããªãã³ãããã¯ïŒäžçç倧æµè¡ïŒã«åããã平垞æã«ã¯éºäŒåæ²»çè¬ã®éçºè£œé åèšãªã©ãäºå®ãããæ°å·¥å Žã¯å»¶ã¹åºé¢ç©çŽïŒäžïŒåå¹³æ¹ã¡ãŒãã«ã§ïŒïŒå¹ŽïŒæã«çå·¥ãïŒïŒå¹ŽïŒæã«å®æããããçµæžç£æ¥çã®è£å©éãæŽ»çšããã
åœç«å»è¬åé£åè¡çç ç©¶æ éºäŒåå»è¬éšããŒã ããŒãžã§ãææçäºé²çšmRNAã¯ã¯ãã³ã®èšåºéçºç¶æ³ãïŒ2023幎2æçŸåšïŒã®äžèЧãå
¬éãããŠããŸãã
2023幎2æ24æ¥æŽæ°ããèšåºéçºäžã®mRNAå»è¬ã
åºå
žïŒåœç«å»è¬åé£åè¡çç ç©¶æ éºäŒåå»è¬éšããŒã ããŒãž


ã€ã³ãã«ãšã³ã¶ãHIVããžã«ç±ãçç¬ç ãªã©ã®mRNAã¯ã¯ãã³ãéçºäžã


以äžã¯ãæ²»ççšã®ã¯ã¯ãã³ã


ããã»ã©å€ãã®mRNAã¯ã¯ãã³ãéçºäžã§ããã§ã«èšåºè©Šéšãé²ããããŠããŸãã
ç¹ã«ãã¢ãã«ã瀟ã®éçºã倿°é²ãã§ããŸãã
ã¢ãã«ã瀟ã¯ãmRNAã¯ã¯ãã³å·¥å Žã®åœå èªèŽã«ã€ããŠã2027幎ã®çšŒåããç®æšã«ããŠããããã§ããäžèšã¯äŒå¡éå®èšäºã§ãããã¿ã€ãã«ã«ãæžãããŠããŸãã
ã¢ãã«ãç€Ÿã¯æšå¹ŽãCovid-19ãã€ã³ãã«ãšã³ã¶ãåŒåžåšç³»ãŠã€ã«ã¹RSVã®æ··åäºé²æ³šå°ãã2023幎å¬ã®ææçã·ãŒãºã³ã«åããŠæºåãé²ããŠãããšçºè¡šããŸããïŒäžèšåç §ïŒã
æ°åã³ãããŠã€ã«ã¹ã®çºçãšãããç·æ¥äºæ
ãããã£ããã«ãå®å
šæ§ã®ç¢ºèªãããããã«ãããŸãŸãmRNAã¯ã¯ãã³ã®éçºãå éããŠããŸãã
ã³ããåã¯ãæ°ããå»è¬åã®éçºã«ã¯ãå°ãªããšã7幎ããããããŠããã¯ãã§ãïŒäžèšåç
§ïŒã
ãã€ãããããªã«ã¹ããŒãéèŠã§ãå®å šæ§ã軜èŠããŠããããšã«ãªã£ãŠããŸã£ãã®ã§ããããããã®ãŸãŸãå®å šæ§ã眮ãå»ãã«ããŠããã¯ãããããŸããã
ä»ãã³ããã¯ã¯ãã³ã«å¯ŸããŠãNoïŒããçªãã€ããããšããä»åŸã®ãå®å šãã«ãã€ãªããã®ã ãšæããŸãã
æ¥çš®åŸã«å¥åº·è¢«å®³ãåããæ¹ãã¡ãããããããããšãããã£ãšåœã«å¯ŸããŠç€ºããŠãããªããã°ããããåç©ãå¥åº·ã§ããããªããªã£ãŠããŸãã§ãããã
éå»ã®è¬å®³äºä»¶ã§ããååŽçã¯å±éºæ§ãç¥ã£ãŠããã®ã«åœæ°ã«å¯ŸããŠé ãç¶ããŠããŸããïŒäžèšåç §ïŒã
åœãèªããŠããã§ã¯é ãã®ã§ããåœæ°ãæ°ã¥ããŠãæ¢ããããªããã°ãåœãå¥åº·ãå®ãããšã¯ã§ããŸããïŒ